Rocket Lab Delivered 835% Returns in Five Years, Is It Still A Buy?

Photo of Alex Sirois
By Alex Sirois Published

Quick Read

  • $1,000 invested in RKLB at its 2021 IPO grew to $9,354, an 835% return fueled by defense contracts and a $2.2 billion backlog.

  • RKLB carries a beta of 2.5 and burned $322 million in free cash flow in FY2025, making it a high-volatility bet rather than a core holding.

  • Rocket Lab is the only publicly tradable pure-play launch company, but Neutron's debut slipped to Q4 2026 after a stage-1 tank test failure.

  • It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor)

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Rocket Lab Delivered 835% Returns in Five Years, Is It Still A Buy?

© 2022 NASA / Getty Images News via Getty Images

Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction) has just under five years of public trading history. Peter Beck’s small-launch pioneer went public via SPAC merger in August 2021, well short of a full decade. That five-year window happens to capture one of the more dramatic transformations in the aerospace sector.

When Rocket Lab debuted, it was a one-rocket story. The Electron small-lift vehicle was reliable but tiny, and the company was burning cash to build a bigger ride called Neutron. Five years later, the pitch is different. Rocket Lab now describes itself as an end-to-end space company spanning launch, satellite buses, and payloads, with a $2.20 billion backlog and 70+ contracted missions. The defense pivot has been the catalyst, headlined by an $816 million Space Development Agency award for 18 Tracking Layer satellites and a slot on the Golden Dome Space Based Interceptor program with Raytheon.

Execution has matched the narrative. Electron logged 21 successful missions in 2025 at a 100% success rate, and acquisitions of Mynaric, Motiv, and Geost expanded the stack. Neutron’s first flight slipped to Q4 2026 after a stage-1 tank test failure, but the contract pipeline kept compounding anyway.

A $1,000 Stake Became Nearly $10,000

1-Year Return

  • Initial Investment: $1,000
  • Current Value: $3,651
  • Total Return: 265.15%
  • S&P 500 (same period): $1,229 (22.91%)

5-Year Return (Since IPO, August 2021)

  • Initial Investment: $1,000
  • Current Value: $9,354
  • Total Return: 835.44%
  • Annualized Return: ~59%
  • S&P 500 (same period): $1,667 (66.7%)

Holding through that ride was not for the squeamish. Shares spent much of 2022 and 2023 underwater, and even the last 12 months produced a 52-week range of $25.24 to $151. The recent gains track tightly with the defense contract wins, 63.5% Q1 2026 revenue growth, and the SpaceX IPO filing pulling the entire sector higher.

I’d Buy It Here, But Not With Conviction

I’d put $1,000 into Rocket Lab today if I believed Neutron debuts on time, the defense backlog converts cleanly, and the market keeps paying a price-to-sales ratio above 100x for that growth profile. The bull case is real: there is no other publicly tradable pure-play launch company with this customer list.

But I’d avoid it if I needed the position to behave well in a drawdown. Rocket Lab still posts GAAP net losses and free cash flow of negative $321.8 million in FY2025, and the beta of 2.499 means any Neutron slip or SpaceX-related sector wobble hurts fast. Personally, I lean buyer at this level, but only as a small, high-volatility sleeve. Anyone sizing it like a core holding is underestimating how violent the next 30% move could be in either direction.

Contact [email protected] for any questions or corrections.

Photo of Alex Sirois
About the Author Alex Sirois →

Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.

Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.

At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.

Continue Reading

Top Gaining Stocks

WDAY Vol: 16,323,850
GDDY Vol: 3,030,517
CSGP Vol: 7,967,696
TTD Vol: 34,667,603
WDC Vol: 8,699,102

Top Losing Stocks

TPR Vol: 8,534,041
CTRA Vol: 73,319,495
CSCO Vol: 61,560,420
GLW Vol: 8,579,035
MPWR Vol: 506,489